Pemetrexed Lilly

RSS

pemetrexed

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Pemetrexed Lilly has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 26/11/2021

Authorisation details

Product details
Name
Pemetrexed Lilly
Agency product number
EMEA/H/C/004114
Active substance
pemetrexed
International non-proprietary name (INN) or common name
pemetrexed
Therapeutic area (MeSH)
  • Carcinoma, Non-Small-Cell Lung
  • Mesothelioma
Anatomical therapeutic chemical (ATC) code
L01BA04
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Eli Lilly Netherlands
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
14/09/2015
Contact address
Grootslag 1-5
PO Box 379
NL-3991 RA Houten
The Netherlands

Product information

18/06/2021 Pemetrexed Lilly - EMEA/H/C/004114 - N/0013

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Malignant pleural mesothelioma

Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer

Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

Assessment history

How useful was this page?

Add your rating